Background: The benefits of chronic coronary total occlusion (CTO) percutaneous coronary interven-
| INTRODUCTION
Chronic coronary total occlusions (CTOs) are diagnosed in approximately one fifth of patients with coronary artery disease (CAD). 1 Due to historically low success rates, increased complication rates, and concerns regarding patient benefit, only the minority of patients with a CTO is referred for percutaneous coronary intervention (PCI). [1] [2] [3] treating CTOs in a most safe, effective, and efficient way, has resulted in high success and acceptable complication rates. 4, 5 Ischemic burden comprising >10% of the left ventricle due to CAD holds prognostic relevance, and several studies have shown extensive ischemia to be present in nearly all patients with a CTO. [6] [7] [8] [9] [10] [11] Therefore, next to symptom recognition and viability detection, ischemia detection forms one of the pillars in judicious patient selection for CTO PCI. Major reductions in ischemia can be achieved after CTO PCI, however, it is more conservatively employed compared with PCI of a non-CTO lesion. 12-14 [ 15 O]H 2 O positron emission tomography (PET) is the gold standard for non-invasive myocardial perfusion imaging, reflecting the composite of the epicardial as well as the microvascular bed, and enabling absolute quantification of myocardial perfusion. 15 The aim of this study was to compare the effects of PCI among CTO versus non-CTO lesions on quantitative myocardial blood flow (MBF) and perfusion defect size.
| MATERIALS AND METHODS

| Study design and participants
The study population consisted of consecutive prospectively recruited ischemia-and viability testing is used for patient selection for CTO PCI. Patients in the non-CTO group were selected from the previously published PACIFIC-trial, comprising only patients without a cardiac history. 15 The study was approved by the institutional Medical Ethics
Review Committee and all patients provided written informed consent.
| Angiographic characteristics
A CTO was defined as a luminal occlusion on invasive coronary angiography for an estimated time of ≥3 months with no or minimal contrast penetration through the lesion (thrombolysis in myocardial infarction [TIMI] flow grades 0-I). 16 The Japanese CTO score (J-CTO) was calculated and CTO PCI was performed according to the hybrid approach, using antegrade wire escalation (AWE), antegrade dissection and reentry (ADR), retrograde wire escalation (RWE), and retrograde dissection and reentry (RDR) techniques 5, 17 . A >90% diameter stenosis or fractional flow reserve (FFR) of ≤0.80 defined a hemodynamically significant non-CTO lesion. In case of multivessel non-CTO PCI, only the vessel with the worst lesion characteristics regarding stenosis severity or FFR value was included for analysis. 3 | RESULTS
| Patient population
Clinical characteristics of the included 92 patients with a CTO and 31 patients with a hemodynamically significant non-CTO lesion are listed in Table 1 . Patients with a CTO had more cardiac risk factors (2.6 AE 1.2 vs. 1.8 AE 1.1; P = 0.01) as compared with patients with a non-CTO lesion. As a result of different patient cohorts, only subjects with a CTO had suffered before from major cardiac events, including prior MI in the CTO territory in 25% of patients.
| Angiographic characteristics
A CTO was located in the right coronary artery in 70% of patients ( 
| Recovery after CTO PCI
Rest MBF in the myocardial area subtended by the CTO was 0.86 AE 0.25 and did not change after PCI (p = .95) ( Table 3 ). In contrast, 
Values are mean AE SD or n (%).Abbreviations: CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; CTO, chronic coronary total occlusion; MI, myocardial infarction; NA, not applicable; PCI, percutaneous coronary intervention; TV, target vessel. Values are n (%). P values indicate the overall difference between groups. Abbreviations: CTO, chronic coronary total occlusion; PCI, percutaneous coronary intervention. ; P = 0.02), whilst MBF during rest (P = 0.56), CFR (P = 0.12) and the residual perfusion defect size (P = 0.25) were comparable. At follow-up, residual ischemia was present in the CTO area in one patient due to a significant stenosis distal to the (former) CTO lesion, and two other patients had residual ischemia in a non-target vessel. After follow-up PET imaging and clinical evaluation, these patients were treated by additional PCI. cardial area subtended by a CTO and by a non-CTO lesion was similar (P = 0.52) and increased after PCI in the non-CTO group only (P < 0.01) to higher levels compared with the CTO group at follow-up (P = 0.03) (displayed in Figure 2 and Table 3 ). Baseline hyperemic MBF was lower in patients with a CTO compared with patients with a non-CTO lesion (P < 0.01). The increase in hyperemic MBF was significant and equivalent after both CTO PCI and non-CTO PCI (P = 0.57). However, higher hyperemic MBF values were maintained in the non-CTO group after PCI (P = 0.03). In the vascular territory of CTOs and non-CTO lesions, CFR values were comparable at baseline (P = 0.17), and improved equally in both groups (P = 0.35) yielding comparable CFR levels after PCI (P = 0.94). As mentioned earlier, the extents of vessel disease and subsequent vessel PCI were similar between groups and regional PET perfusion results were not different between patients with one, two and three vessel disease (all comparisons P > 0.05).
| Effects of CTO PCI versus non-CTO PCI on perfusion defect size
The perfusion defect size, as measured in myocardial segments, comprised at baseline more myocardium in patients with a CTO compared with patients with a non-CTO lesion (P < 0.01) (Figure 3 ). The effect of PCI on the perfusion defect size was similar in both groups (P = 0.14), resulting in insignificantly different and small residual perfusion defect sizes (P = 0.054). 
| DISCUSSION
| Patient selection and characteristics
Patients with a CTO had a more severe cardiac risk profile compared with patients with non-CTO lesions. 25% of patients with a CTO suffered from prior MI even though only patients with preserved LVEF were included in this analysis. The patient groups were selected from prior studies with different in-and exclusion criteria, which can (partially) explain these differences. However, patients with a CTO are known to have more extensive CAD and comorbidity than patients with CAD without a CTO. 1 All PET perfusion results were corrected for age and gender when comparing between groups, and by selecting patients with a preserved LVEF only, the extent and influence of previous MI was attempted to be minimized.
| The influence of a CTO versus a non-CTO lesion on myocardial perfusion
To achieve a genuine comparison between CTOs and non-CTO lesions, only FFR defined hemodynamically significant lesions were included in the non-CTO group. Thresholds for significant CAD with [ consistently demonstrated that well-developed collaterals cannot preserve adequate blood supply to a CTO territory during increased demand. [9] [10] [11] In addition, prior MI, although sometimes unrecognized in patients with a CTO, and microvascular dysfunction, are regularly present in the myocardial area supplied by a CTO. 21, 22 
| Effects of CTO PCI versus non-CTO PCI on myocardial perfusion
A significant increase in rest MBF was seen after non-CTO PCI, whilst no change occurred after CTO PCI. Hypothetically this increase after non-CTO PCI can be the recovery of chronic hypoperfusion in former hibernating myocardium. Overall viability in the target vessel territory was preserved in all individuals. However, 25% of patients in the CTO group had suffered previously from MI in the vascular territory of the CTO, and this might have resulted in relatively less hibernating myocardium present in these patients at baseline. Improvement in hyperemic MBF and CFR after CTO PCI and non-CTO PCI was comparable, leading to normalization of the above-mentioned indices in both patient groups. 20 Still, relatively higher MBF levels during hyperemia were observed after PCI in the non-CTO group. With lower levels at baseline and in the presence of potentially more microvascular In an additional analysis in the total cohort of patients comparing target lesions in the RCA with target lesions in the LAD, however, comparable hyperemic MBF levels were found at baseline (P = 0.52), at follow-up (P = 0.70), and in change of hyperemic MBF (P = 0.98).
Another possible explanation for relatively lower (although already normalized) hyperemic MBF levels after CTO PCI would be the procedure leading to suboptimal results. Because the vessel is totally occluded, a CTO can be crossed through the luminal plaque or around the lesion through the subintimal space by means of a DR technique.
Higher rates of restenosis and repeat target vessel revascularization after the usage of wire-based DR techniques have been reported previously. 24, 25 After the introduction of more controlled device-based DR techniques, however, wire-based DR techniques are increasingly being used as a bailout strategy when other strategies in CTO PCI fail.
This development has led to acceptable repeat revascularization rates after usage of DR techniques comparable with intraplaque crossing techniques. 26 In this study in the CTO group, intraplaque crossing and stenting resulted in relatively higher hyperemic MBF after PCI compared with a successful DR technique. The (inappropriate) usage of a DR technique can lead to long dissection planes with a potential for side branch loss, longer stent lengths and stent under-sizing due to hematoma formation, and in this study these unfavorable features could hypothetically have led to less recovery of hyperemic MBF.
However, the recently published results of the randomized IMPACTOR-CTO trial showed that only a marginal nonsignificant reduction in ischemic burden could be realized with optimal medical therapy alone (without successful crossing and stenting) in patients with a CTO. 27 Although hyperemic MBF after the usage of DR techniques was relatively lower in this study, it should be noted that these techniques led to successful CTO crossing and subsequent reduction in ischemic burden in 48% of the patients, and they can be considered as essential additives in CTO PCI. 5 The potential differences in restoration of myocardial perfusion after intraplaque crossing and DR Perfusion defect size in myocardial segments before and after PCI of a CTO and a non-CTO lesion. At baseline, the average perfusion defect size was significantly more comprehensive in the CTO group compared with the non-CTO group. Percutaneous revascularization led to significant improvements with small residual perfusion defects in both groups as a result. CTO becomes less of a boundary to achieve satisfying results, which is illustrated by the recovery of perfusion after CTO PCI in this study.
This study adds to the scarce body of evidence that among patients with ischemia as indication for revascularization, CTO PCI should be applied in a similar way as non-CTO PCI. With contemporary high success and acceptable complication rates in CTO PCI, it is a treatment strategy that should readily be considered albeit with appropriate patient selection. unclear. 30 With lack of angiographic control at time of follow-up PET imaging, it cannot be excluded that recurrent luminal narrowing has influenced the results in a negative manner in some patients. The mean time interval between PCI and follow-up PET was 110 days in the CTO group and 23 days in the non-CTO group due to different imaging protocols in the two patient cohorts. With absence of restenosis, a gradual increase of perfusion after angioplasty at 1 week and 3 months follow-up has been reported previously. 31 If the duration between PCI and follow-up PET imaging in the non-CTO group would have been longer, this could potentially have led to more advantageous results. The recently published results of the randomized shamcontrolled ORBITA trial showed comparable improvements in patient health status after PCI and optimal medical therapy despite the significant improvements in invasive and non-invasive perfusion indices after PCI. 32 In this study, patient symptoms were not systematically obtained after PCI during follow-up, and therefore lacks the exploration of a possible correlation between improvement of (hyperemic) MBF and patient symptoms or quality of life.
| CONCLUSION
In general, hyperemic myocardial perfusion is slightly more hampered in patients with a CTO before and after PCI. Percutaneous revascularization of CTOs, however, improves hyperemic MBF, CFR, and the perfusion defect size similar to PCI of hemodynamically significant non-CTO lesions, leading to satisfying results.
